Daily Updates
Replimune Won Its Adcomm After the FDA Called Its Data “Not Interpretable”
The FDA’s advisory committee process just produced the most contradictory week of the year, and it landed exactly where we said the uneven reset would
Your fast, high-signal look at everything that moved biotech, medtech, and pharma today. The BioMed Nexus Daily Update delivers the most important regulatory moves, trial readouts, deals, and industry developments in one concise, easy-to-scan report. Updated every weekday morning.
The FDA’s advisory committee process just produced the most contradictory week of the year, and it landed exactly where we said the uneven reset would
The dealmaking story keeps widening, and today it moved down market. Supernus and Indivior agreed to an all stock merger of equals that creates a
The Financial Times reported that AstraZeneca and Bristol Myers Squibb have been in talks to combine, a deal that would create a pharmaceutical group valued
Roche just made the kind of hard choice that tells you where the whole industry’s head is. The company is discontinuing acmopatide, a drug that
The day we have pointed to all week is here, and the tariffs are more complicated and more revealing than the 100% headline suggests. As
The GLP 1 story keeps outgrowing the box everyone put it in. Altimmune reported that pemvidutide, its GLP 1 and glucagon drug, curbed heavy drinking
The FDA’s relationship with its own advisory committees is getting strange, and Capricor is caught in the middle of it. Ahead of this week’s advisory
Two immunology stories landed on opposite sides of the same coin this week, and together they tell you how hard this business is even for
Retatrutide is the drug the whole obesity field has been waiting on, and over the weekend it delivered again. Lilly reported positive topline results from
On Monday we wrote that GSK’s habit of cutting losing programs fast—camlipixant in chronic cough, the Alector neurodegeneration pact before it—was defensible discipline that came